• Exousia Pro Inc. outlined a plan to shift into an integrated healthcare platform combining telehealth revenue with commercialization of in-house diagnostics.
• Management targets an initial commercial launch of its Nanog saliva-based cancer screening test in September or October 2026, with IRB clinical testing set to start shortly.
• Strategy relies on scaling existing acquired operations generating $135,000 to $140,000 per month to fund near-term execution without dilution.
• Go-to-market plan centers on a proprietary distribution channel reaching over 300,000 active patients monthly, adding 5,000 new patients daily.
• Additional growth plan calls for a prescription-fulfillment program targeting about 2,000 prescriptions per day at an estimated $4 per prescription.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exousia Pro Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606170700PRIMZONEFULLFEED9748348) on June 17, 2026, and is solely responsible for the information contained therein.